Skin Cancer

P=N/A, N=156, Recruiting, Pierre Fabre Medicament | Trial primary completion date: Nov 2025 --> Mar 2026

P=N/A, N=40, Not yet recruiting, University of Pittsburgh

P=N/A, N=90, Recruiting, Sunshine Coast University Hospital | Not yet recruiting --> Recruiting

As the catalog of identified fusions continues to grow, an updated understanding of these entities is essential for accurate classification and for anticipating potential therapeutic vulnerabilities. This review aims to provide a practical, contemporary reference for the diagnostic pathologist navigating the rapidly evolving field of fusion-driven dermatopathology.

In vivo, topical application results in deep skin and tumor penetration, significantly inhibiting tumor growth and enhancing immune activation with minimal toxicity. Taken together, these results highlight HA-LNP as a promising, clinically translatable platform for localized, mRNA-based cancer immunotherapy.

In this review, we present the current therapeutic opportunities and future directions of immunotherapy in the management of malignant melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma, accompanied by a brief overview of their mechanisms of action. Ambrus L, Balatoni T. Immunotherapy of cutaneous neoplasms.

Gene expression analysis was performed to evaluate key signaling molecules involved in cell apoptosis, such as bax, bcl-2, cytochrome c, caspases (cas)-3 and -9 and p53. The expression levels of cas-3 and cas-9, executors in the apoptosis pathway, were significantly upregulated in the SK-MEL-28 cells treated with DH-P for 48 h, further confirming that cell death may occur through an apoptosis mechanism.

Because the C2 subtype involves the MHC-II and PROS signaling pathways, which have been shown to have roles in neuroimmunology, neuroinflammation, and pain regulation, it may serve as a hub for neuro-immune interactions in the tumor microenvironment. Precision treatments for melanoma may be advanced by focusing on the FOSL1 or C2 subtype pathways, which may assist in overcoming immunotherapy resistance.

Treatment similar to that of melanoma was commenced with pembrolizumab, which he completed without significant side-effects...Paediatric metastatic atypical DPN is not documented. Paediatric oncology supraspecialist MDT consensus was mandatory for management and support for our patient.

Dermatologists are the primary referrers, underscoring their critical role in early recognition. Enhanced awareness across specialties is crucial to improve diagnostic timelines and outcomes.

J Dermatol Dermatol Surg 2020; 24: 5-12). This highlights the need to consider routine phototesting in this patient demographic to better define their thresholds and tailor a more personalized photoprotective treatment plan accordingly.

As SLNB becomes increasingly integrated into clinical practice, our study highlights the important role of SLNB in managing higher-risk patients and providing access to SACT. Why mortality significantly differs between those diagnosed through teledermatology vs. face-to-face needs further investigation, but it highlights the safety of teledermatology-directed care in the skin cancer pathway.